INTRODUCTION {#sec1-1}
============

Alzheimer\'s disease (AD) is one of the most serious neurodegenerative diseases and the most common cause of dementia in aging population affecting approximately 26 million people worldwide, and whose prevalence has been calculated to triplicate by 2050.\[[@ref1][@ref2]\] AD is characterized clinically by progressive impairment in memory, cognition, and behavioral functions.\[[@ref3]\] It is believed that AD initiates with synaptic impairment, neuronal loss, microglial cell proliferation, and is followed by inflammation.\[[@ref4][@ref5]\] The neuropathological feature of AD is complex, including cerebral accumulation of extracellular amyloid-β (A-β) plaques and intraneuronal neurofibrillary tau tangles composed of dystrophic neuritis and hyperphosphorylated tau protein.\[[@ref6]\] According to the "amyloid hypothesis," the soluble A-β in the brain, plays an important role in the development of AD.\[[@ref7]\] Despite catastrophic increase of dementia patients worldwide, no effective treatment is available yet, although several acetylcholine esterase inhibitors such as donepezil, rivastigmine, and galantamine usually were used, but these medicines can only slow down the progression of dementia, rather than restoring brain function in a real clinical situation. Therefore, alternative and multitargeted therapeutic strategies are urgently needed to prevent or treat Alzheimer\'s disease.\[[@ref8][@ref9]\] Because AD arises via multiple pathological or neurotoxic pathways, herbal medicines as a result of multifunction, multitarget characteristics have potential of optimum pharmaceutical and nutraceutical effects on AD patients.\[[@ref10]\]

Medicinal herbs-derived agents have different mechanisms from conventional drugs, which can be effective in clinical treatment. Herbs contain some of the most powerful natural antioxidants and bioactive secondary metabolites such as flavonoids, phenols, or phenolic components that make them valuable in their antioxidant and antiaging effects.\[[@ref11]\] *Rosa damascena* is a plant that belongs to genus *Rosa* and family Rosaceae. Rosaceae are well known as ornamental plants and have referred to the king of flowers. Some members of the Rosaceae family have long been used for food and medical purposes. Most of the studies showed that *R. damascena* as a natural plant with high source of flavonoids such as quercetin, kaemferol, myricetin, gallic acid, and their glycoside derivatives may have curable effect on treatment of diseases.\[[@ref11][@ref12]\] It has been shown that essential oil of *R. damascena* retards the development of behavioral seizures in amygdale electrical kindling and possesses ability of contract kindling acquisition.\[[@ref13]\] There is considerable evidence suggesting that extract of the *R. damascena* significantly induces the neurite outgrowth and inhibits the A-β fibrilization and deposition in brain.\[[@ref14]\] Also it is shown that the *R. damascena* oil can relieve human stress and depression.\[[@ref15]\] Flavonoids perform a multiplicity of neuroprotective functions within the brain, including neural protection against neurotoxin injuries, neuroinflammative suppression and promotion of memory, learning, and cognitive function. These effects could be mediated by flavonoids that inhibit apoptosis, promote neuronal survival and synaptic plasticity. They can also promote cerebrovascular blood flow, angiogenesis, neurogenesis, and neuronal morphology.\[[@ref16]\] The aim of the current study was to determine the effects of methanolic extract of *R.damascena* on behavioral functions in a rat model of amyloid- β (1- 42) induced Alzheimer\'s disease.

MATERIALS AND METHODS {#sec1-2}
=====================

Methanolic extraction of *R. damascena* {#sec2-1}
---------------------------------------

Dried fresh flowers of *R. damascena* Mill was purchased from Isfahan Pharmaceutical Sciences Research Center (Iran). It was ground to a fine powder (2 kg) and then macerated with methanol (10 L). Extraction procedure was performed three times and each time for 4 consecutive days with intermittent stirring (1 h stirring at every 12 h interval) using magnetic stirrer until the extract was light colored. The combined extracts were filtered and concentrated under reduced pressure in a rotary vacuum evaporator (200 mbar) in a water bath at 40°C. Dried gummy extract (380 g) was stored in 4°C until use.\[[@ref11]\]

HPLC analysis and extract standardization {#sec2-2}
-----------------------------------------

High-performance liquid chromatographic (HPLC) analysis was performed on a Waters system, equipped with *515 HPLC* pump, UV--Visible detector (2487 dual absorbance) operated at 365 nm, and millennium software for the determination of quercetin in the extract. After acid hydrolysis of 100 mg of the extract (1 h in 2N HCl, at 95°C), the hydrolyzed flavonoids were extracted through ethyl acetate to 5 mL. Then 20 μl of the sample injected into a Nova-Pak C18, 3.9 × 150 mm (Waters, Milford, MA, USA) using H~3~PO~4~ 10 mM in water (solvent A) and acetonitrile (solvent B) with gradient elution at a flow rate of 0.8 mL/min. A standard calibration curve in the range of 100--1000 μg/mL for quantitative analysis was prepared using different concentrations of quercetin (Sigma Aldrich, USA) as standard material (100, 200, 500, and 1000 μg/mL). The relationship between the concentration and peak-area of standard was measured using the minimum square method (R2 value).\[[@ref17]\]

Acute toxicity studies and determination of median lethal dose (LD50) {#sec2-3}
---------------------------------------------------------------------

Toxicity is defined as "the potential of a substance to exert a harmful effect on humans or animals, and a description of the effect and the conditions or concentration under which the effect takes place."\[[@ref18]\]

Acute toxicity is involved in the estimation of LD50 (the dose which has proved to be lethal (causing death) to 50% of the tested group of animals). Determination of acute oral toxicity is usually an initial screening step in the assessment and evaluation of the toxic characteristics of all compounds.\[[@ref19][@ref20]\]

Assignment and housing of the animals for toxicity studies {#sec2-4}
----------------------------------------------------------

Each animal was assigned a unique identification number. Thirty-six male Wistar rats (200--250 g) were housed six per cage. Six rats in each group at each dose level were chosen. In the present study, rats were gavaged via a gastric tube with increasing six series doses of *R. damascena* extract to get 50% lethality according to [table 1](#T1){ref-type="table"}. One dose being used per group. The animals were observed in several times up to 72 h for survival and morbidity.\[[@ref21][@ref22]\] Median lethal dose (LD50) was calculated as given in [table 1](#T1){ref-type="table"}.

###### 

Determination of (LD50)

![](ABR-4-131-g001)

Dose levels and dose selection {#sec2-5}
------------------------------

This is based on the results of (LD50) finding test. At least three dose levels were used, spaced appropriately to produce test groups. For dose selection, 20% of (LD50) 6000 mg/kg was determined as the highest dose (1200 mg/kg) and decreasing spaced doses of 600 and 300 mg/kg were considered as middle and low doses, respectively, in our experimental study.\[[@ref23]\]

Animals and stereotaxic surgery {#sec2-6}
-------------------------------

Male Wistar rats (200--250 g) were housed four per cage and maintained on a 12 h light--dark cycle in an air-conditioned constant temperature (23 ± 1°C) room, with food and water made available *ad libitum*. The Ethics Committee for Animal Experiments at Isfahan University of Medical Sciences approved the study, and all experiments were conducted in accordance with the international guiding principles for biomedical research involving animals, revised in 1985. Initially, all animals were randomly divided into 6 groups (*n* = 10) for evaluation of baseline training performance in Morris water maze and passive avoidance tests. After spatial acquisition phase of Morris water maze and training (learning) phase of the passive avoidance test, animals were grouped as following: First group = control, Second group = sham, Third group = Alzheimer\'s disease + Normal saline, Fourth group = Alzheimer\'s disease + 300 mg of *R. damascena* extract, Fifth group = Alzheimer\'s disease + 600 mg of *R. damascena* extract and sixth group = Alzheimer\'s disease + 1200 mg of *R. damascena* extract. The protocol of experimental design is summarized in [Figure 1](#F1){ref-type="fig"}.

![Experimental schedule of the research design during the course of the study](ABR-4-131-g002){#F1}

Rats (groups 3^rd^ to 6^th^) were anesthetized by intraperitoneal injection of chloral hydrate (350 mg/kg) and placed into stereotaxic device (Stoelting, Kiel, WI, USA). A heating pad was used to maintain body temperature at 36.5 ± 0.5°C. An incision was made along the midline, the scalp was retracted, and the related area was cleaned and dried. In addition, lidocaine and epinephrine solution (0.4 mL) were injected in several locations surrounding the incision. In order to make minimum brain trauma during infusion, injections were performed very slowly (1 μL/min) using a microinjection pump. Amyloid-β (1-42) (Sigma) was dissolved in phosphate buffered saline (PBS 0.1 M) and aliquots at a concentration of 1 μg/μL were stored at −20°C until used. For induction of aggregation, aliquots of amyloid-β (1-42) were incubated for 5 days at 37°C before administration. Then 3 μg/3 μL of fibrillar A-β (1--42) or vehicle (PBS 0.1) were injected into the CA1 area of hippocampus at the following coordinates: Incisor bar −3.3 mm, −3.6 mm anterior-posterior to the bregma, 2.4 mm lateral to the sagittal suture, 2.8 mm dorsoventral from top of the skull bilaterally according to the atlas by Paxinos and Watson.\[[@ref24]\] The needle was kept in place for 5 min to allow the injected solutions and tissue to equilibrate and avoid the possible reflux through the needle track. Incisions were ligated with silk thread. In sham group, same surgery was performed except that PBS was injected in CA1. No surgery was done in the control group.

Morris water maze {#sec2-7}
-----------------

The circular tank (180 cm in diameter) was filled with water (22 ± 2°C) made opaque and was surrounded by a variety of extramaze cues. The tank was divided into four equal quadrants (northeast, northwest, southwest, and southeast) and four start positions were located at the intersection of the quadrants \[[Figure 2a](#F2){ref-type="fig"}\]. A platform (12.5 cm in diameter) was placed in the northeast (the target quadrant) and submerged 2.0 cm below the water surface where it remained for all spatial trials.\[[@ref25][@ref26][@ref27]\] Twenty-four hours before water maze training, all rats were habituated to the water and apparatus. In the spatial acquisition phase, the rats learned to find a submerged platform using extramaze cues. Each rat participated in eight trials that were organized into two blocks of four trials (one trial/start position within a block). Each block was considered a separate test session and blocks were separated by 30 min. For each trial, the rat was given a maximum time of 60 s to locate the platform. After mounting the platform, the animals were allowed to remain there for 30 s, and then were placed in a holding cage for 30 s until the start of next trial. If the rat did not locate the platform within 60 s, it was guided to it by the experimenter. After completion of spatial acquisition phase, the animals were returned to their home cages until the initiation of probe trials in the test days. During the different phases of the maze, the animals were monitored by digital camera fixed 2 m above the maze and different parameters were analyzed using computer-based software (Radiab 1). Swim time (in s), swim distance (in cm), and swim speed (in cm/s) were recorded.

![(a) Tank of the Morris water maze and site of the platform. (b) Schematic representation of the passive avoidance test apparatus](ABR-4-131-g003){#F2}

The first and second probe trials (spatial retention) 21 days after surgery and following extract treatment were performed, respectively. In the probe trials, the hidden platform was removed and animals were allowed to swim freely for 60 s. During the probe trials, the percentage time in target quadrant was calculated. Cued acquisition task conducted 20 min after completion of the probe trials in order to test their nonmnemonic aspects of water maze performance such as swimming ability, motivation, and visual ability. In this phase, the platform was elevated above the water surface and was placed in different positions, and rats were allowed to swim freely toward visible platform for 60 s. Twenty-one days after operation the 1^st^ probe trial of Morris water maze and passive avoidance tests were performed and memory impairment was confirmed in groups 3--6.

Then dried *R. damascena* extract was dissolved in normal saline 0.9% +1% Tween 20, and then was administrated orally at 300, 600, 1200 mg/kg/day for 1 month via gavage in groups 4--6. Sham and 3^rd^ groups received only normal saline at the same time. After *R. damascena* extract treatment 2^nd^ probe trial of Morris water maze and passive avoidance tests were performed to evaluate the effects of extract on learning and spatial and long-term memories.

Passive avoidance test {#sec2-8}
----------------------

The apparatus for the step-through passive avoidance test is an automated shuttle-box divided into an illuminated chamber and a dark chamber of the same size (20 × 25 × 30 cm each) by a wall with a guillotine door\[[@ref28][@ref29][@ref30]\] \[[Figure 2b](#F2){ref-type="fig"}\]. In the present study, passive avoidance test was used as an index of long-term memory.

In the adaptation trial, each rat was trained to adapt to the step-through passive avoidance apparatus. The animal was placed into the illuminated chamber, facing away from the dark chamber. After 60 s, the door between these two boxes was opened and the rat was allowed to move into the dark chamber. The training trial was performed 24 h after the adaptation trial. In training trial, each rat was placed individually in the illuminated chamber, and once it entered the dark chamber an electric shock (40 V, 0.3 A, 2 s) was delivered to its feet through the floor grid. The rat was immediately removed and returned to cage. The first probe trial (retention trial) was conducted 21 days after surgery, in which rats were placed again in illuminated chamber and the interval (step-through latency) between placement in illuminated chamber and entry to the dark one was recorded. If the animal did not enter the dark chamber within 5 min, the test was terminated and the step through latency was recorded as 300 s. Memory impairment was confirmed in groups 3--6. Then *R. damascena* extract was applied as described previously. After *R. damascena* extract treatment, 2^nd^ probe trial of passive avoidance was performed to evaluate the effects of extract on long-term memory.

Statistical analysis {#sec2-9}
--------------------

Data were expressed as mean ± SEM (standard error of mean) and were analyzed using either SPSS version 19 or GraphPad Prism^®^ 5.0. software. Statistical analysis was performed using the following tests. The escape latencies, swim distance, and swim speed in the water maze were analyzed by two-way analysis of variance (ANOVA) for between-subject differences between groups and repeated measures (within subjects) for effects across block interval 1--2 ("BLOCK" effect). The probe trials data for percentage of time in target quadrant were analyzed by multivariate ANOVA followed by Tukey\'s honestly significant difference (HSD) test as a *post hoc* analysis. One-way ANOVA followed by Tukey\'s HSD multiple comparison test as a *post hoc* analysis were performed for evaluation of training trial and retention trials of passive avoidance test. A value of *P* \< 0.05 was considered statistically significant.

RESULTS {#sec1-3}
=======

HPLC standardization of the extract {#sec2-10}
-----------------------------------

Methanolic extraction of the *R. damascena* was performed and standardized using quercetin as the bioactive marker for standardization of the extract. Quercetin peak of extract appeared at a retention time of 13.48 min and using calibration curve, the extract was standardized to contain 548.89 ± 20.23 mg/100 g of the total quercetin (0.55% w/w) \[Figure [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}\]. By using of millennium processing software, the calibration curve was determined by linear regression in the range of 100--1000 μg/mL. The regression equation was *y* = 86419*x* + 794975, where *x* was the concentration of total quercetin in the extract (μg/mL) with the correlation co-factor (R2) of 0.998 \[[Figure 3c](#F3){ref-type="fig"}\].\[[@ref14]\]

![(a) HPLC chromatogram of quercetin standard at 365 nm; 20 μL of the quercetin standard (Sigma Aldrich, USA) in the range of 100--1000 μg/mL was injected into a Nova-Pak C18, 3.9 × 150 mm (Waters, Milford, MA, USA) using H~3~PO~4~ 10 mM in water (solvent A) and acetonitrile (solvent B) with gradient elution at a flow rate of 0.8 mL/min. Quercetin peak appeared at a retention time of 13.64 min. (b) HPLC chromatogram of *Rosa damascena* extract at 365 nm. After acid hydrolysis of 100 mg of the extract (1 h in 2N HCl, at 95°C), the hydrolyzed flavonoids were extracted through ethyl acetate to 5 mL. Then 20 μL of the sample was injected into a Nova-Pak C18, 3.9 × 150 mm (Waters, Milford, MA, USA) using H~3~PO~4~ 10 mM in water (solvent A) and acetonitrile (solvent B) with gradient elution at a flow rate of 0.8 ml/min. Quercetin peak of the extract appeared at a retention time of 13.48 min. (c): Calibration curve of quercetin using HPLC method and acetonitrile/water as mobile phase with pH adjusted to 2.3 at 365 nm. Using the millennium processing software, the calibration curve was determined by linear regression in the range of 100--1000 μg/mL. The regression equation was *y* = 86,419*x* + 7, 94,975](ABR-4-131-g004){#F3}

Evaluation of the spatial acquisition phase of the Morris water maze before animal model induction {#sec2-11}
--------------------------------------------------------------------------------------------------

There were no significant differences in the mean time latency (*F* (5, 54) =0.041, *P* = 1 \>0.05), mean swimming distance (*F* (5, 54) =0.128, *P* = 0.9 \>0.05), and mean swimming speed (*F* (5, 54) =0.426, *P* = 0.8 \>0.05) in blocks 1 and 2 of the spatial acquisition among all groups before application of A-β \[Figure [4a](#F4){ref-type="fig"}--[c](#F4){ref-type="fig"}, blocks 1 and 2\], but repeated measure test showed a significant difference in escape latency, swimming distance, and swimming speed (*F* (1, 54) = 74.96, *P* \< 0.001); (*F* (1, 54) = 397.22, *P* \< 0.001); (*F* (1, 54) = 20.14, *P* \< 0.001 respectively) between blocks 1 and block 2 were observed \[Figure [4a](#F4){ref-type="fig"}--[c](#F4){ref-type="fig"}, blocks 1 and 2\] to locate the platform across blocks of trials, indicating spatial acquisition performance in all groups improved significantly during the training days and were able to learn the task.

![Behavioral assessment. In spatial acquisition phase there were no significant differences in block 1 and 2 among the six groups before application of amyloid-β, but Repeated measure test showed a significant reduction in (a) escape latency (*P* \< 0.001), (b) swimming distance (*P* \< 0.001), and (c) swimming speed (*P* \< 0.001) in 2^nd^ block compared with 1^st^ block to locate the platform across blocks of trials](ABR-4-131-g005){#F4}

Evaluation of the training trial of the passive avoidance test before animal model induction {#sec2-12}
--------------------------------------------------------------------------------------------

One-way ANOVA showed that the step-through latency did not differ in the training trial among the six groups before operation (*F* (5, 54) =0.069, *P* = 0.9 \> 0.05) \[[Figure 5](#F5){ref-type="fig"}\].

![In training trial of the Passive avoidance test, there were no significant differences in step-through latency among the six groups (*P* = 0.9)](ABR-4-131-g006){#F5}

*R. damascena* extract improved the spatial learning and memory parameters in a rat model of Alzheimer\'s disease {#sec2-13}
-----------------------------------------------------------------------------------------------------------------

Multivariate ANOVA analysis showed significant differences in 1^st^ probe trial among groups (*P* \< 0.001) \[[Figure 6](#F6){ref-type="fig"}\]. *Post hoc* Tukey\'s HSD analysis showed that, the mean percentage of time spent in target quadrant in A-β-injected groups (3^rd^ to 6^th^) after 21 days surgery was significantly decreased in comparison to control and sham groups (*P* \< 0.001), but no significant differences were demonstrated in mean percentage of time spent in target quadrant between control and sham groups, (*P* = 0.9 \> 0.05). These results showed that A-β--induced learning and memory impairment in the rats. Multivariate ANOVA analysis showed that mean percentage of time spent in target quadrant in 2^nd^ probe trial after one month *R. damascena* extract treatment was significantly increased among groups (*P* \< 0.001) \[[Figure 6](#F6){ref-type="fig"}\]. *Post hoc* Tukey\'s HSD analysis showed that, mean percentage of time spent in target quadrant was significantly increased in extract-treated groups (5^th^ and 6^th^ groups) relative to 3^rd^ group, which had received normal saline (*P* = 0.006 \< 0.05, *P* \< 0.001, respectively), but mean percentage of time in target quadrant in 4^th^ group did not significantly increase relative to 3^rd^ group (*P* = 0.3 \> 0.05). Also mean percentage of time in target quadrant in 6^th^ group was significantly increased in comparison to 4^th^ (*P* = 0.002 \< 0.05). Taken together, these results showed that *R. damascena* extract improved spatial learning and memory in a dose-dependent manner.

![Effects of the amyloid-β and *Rosa damascena* extract on spatial memory during the first (A, white color) and second (A, black color) probe trials, respectively, as measured by mean percentage time in target quadrant. \*\**P* \< 0.01; \*\*\**P* \< 0.001 different from the control and sham groups. ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 different from the Aβ-injected group (Alz + NS), ^@^*P* \< 0.05, ^@@@^*P* \< 0.001 different from the Aβ-injected group (Alz + 300)](ABR-4-131-g007){#F6}

*R. damascena* extract improved the long-term memory parameters in a rat model of Alzheimer\'s disease {#sec2-14}
------------------------------------------------------------------------------------------------------

One-way ANOVA showed that significant differences in mean step-through latency among groups were observed following surgery in the 1^st^ probe trial (*F* (5, 54) =275.94, *P* \< 0.001) \[[Figure 7](#F7){ref-type="fig"}\]. *Post hoc* Tukey\'s HSD analysis showed that mean step-through latency reduced in Aβ-treated groups (3^rd^ to 6^th^) compared with control and sham groups (*F* (5, 54)=119.24, *P* \< 0.001). One-way ANOVA demonstrated that following extract treatment, step-through latency significantly increased among groups (*P* \< 0.001) \[[Figure 7](#F7){ref-type="fig"}\]. The mean step-through latency in groups 5 and 6 was significantly increased in comparison to 3^rd^ group (*P* \< 0.001). Mean step-through latency in 4^th^ group did not significantly increase relative to 3^rd^ group (*P* = 0.07). This parameter in 5^th^ and 6^th^ groups significantly increased when compared with 4^th^ group (*P* \< 0.001). All together these data show that *R. damascena* extract in medium (600 mg/kg) and high dose (1200 mg/kg) improved long-term memory in a dose-dependent manner.

![Effects of the amyloid-β and *Rosa damascena* extract on long-term memory during the first (B, white color) and second (B, black color) probe trials, respectively, as measured by mean time step-through latency. \*\**P* \< 0.01; \*\*\**P* \< 0.001 different from the control and sham groups. ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 different from the Aβ-injected group (Alz + NS), ^@^*P* \< 0.05, ^@@@^*P* \< 0.001 different from the Aβ-injected group (Alz + 300)](ABR-4-131-g008){#F7}

DISCUSSION {#sec1-4}
==========

The goodness of usual anti-AD drugs, is just a temporary relief of clinical symptoms and signs of dementia, but the efficacy of these cholinesterase inhibitors in AD treatment is not supported by any high-quality and long-lasting clinical trials.\[[@ref9]\] These medications cannot cure Alzheimer\'s dementia or stop the disease progression.\[[@ref31][@ref32]\] Because AD is a multifactorial disease, using multifunctions and multitargeted agents have been considered extensively.\[[@ref33][@ref34]\] Enormous medical combination therapies have been proposed to cure Alzheimer\'s disease.\[[@ref35]\] Herbal medicines as a result of multifunction, multitarget characteristics have potential of optimum pharmaceuticals and nutraceuticals effects on AD patients.\[[@ref10]\] Preclinical and epidemiological studies suggest that herbal drugs might be effective at reversing neurodegenerative pathology and age-related declines in neurocognitive performance.\[[@ref36]\] Herbal drugs may act to protect the brain in a number of ways, including by protection of vulnerable neurons, promotion of peripheral and cerebral vascular system, enhancement of existing neuronal function or by stimulating neuronal regeneration and inhibition of neuroinflammation.\[[@ref37]\] Moreover, medicinal herbs--derived drugs are natural and hence safer than synthetic drugs, and that a complex mixture of herbs can effectively treat complex diseases. These advantages may account for the sudden increase in herbal use in the last decade.\[[@ref38]\] In addition, some of the experimental reports suggest that some herbs may have neuroprotective effects against amyloid-β.\[[@ref39][@ref40]\]

The present study examined the effects of a methanolic extract of *R. damascene* on behavioral deficits in a rat model of amyloid-β (Aβ1-42)--induced Alzheimer\'s disease. Morris water maze and passive avoidance tests were used for examination of behavioral changes caused by amyloid-β and possible effect of *R. damascena* extract on learning, spatial memory, and long-term memories.\[[@ref29][@ref30][@ref41][@ref42]\] The memory impairment induced by intra-CA1 injection of Aβ in our study was in agreement with Yamada *et al*.\[[@ref43]\] One month after *R. damascena* extract treatment, spatial memory and long-term memory were improved, whereas cognitive decline was reversed in a dose-dependent manner. The neuroprotective effect of *R. damascena* against cytotoxicity of A-β was investigated by Awale *et al*. *in vitro*. They showed that *R. damascena* extract significantly causes neurite outgrowth and suppresses the Aβ - induced atrophy and cell death. Moreover, the length of dendrite in the cells treated with *R. damascena* extract was similar to those of nerve growth factor (NGF)--treated cells.\[[@ref14]\] Significant effect of *R. damascena* on Aβ-injected groups in our study could be because of its multifactorial effects of bioactive flavonoids, polyphenols, and secondary active metabolites. Kumar *et al*. had detected and quantified some of polyphenols including gallic acid, rutin, quercitrin, myricetin, quercetin, and kaempferol, in methanolic extract of *R. damascena* by using improved HPLC analysis method.\[[@ref17]\] In agreement with Kumar *et al*., our HPLC analysis showed that quercetin as bioactive compound exists in the *R. damascena* extract. Flavonoids comprise the most common group of polyphenolic compounds in the human diet and are found ubiquitously in plants.\[[@ref44][@ref45]\] The neuroprotective effects of *R. damascena* were mediated by flavonoids that induce memory and cognitive improvement function via scavenging free radicals, and releasing neurotransmitter (acetylcholine). Other multifunctional effects of flavonoids include antioxidant, antiapoptotic, anti-inflammatory, anticholinesterase, antidepressant, and modulation of signaling pathway cascade\[[@ref44][@ref45][@ref46][@ref47][@ref48]\] and cerebrovascular blood flow improvement.\[[@ref49]\] Cellular and molecular mechanisms of flavonoids effects may carry out via protein kinase activation and phosphatase inhibition that could lead to activation of cyclic AMP-response element-binding protein (CREB). CREB could increase blood flow, angiogenesis, neurogenesis, dendritic spine growth, neuronal communication, and synaptic plasticity via production and activation of neurotrophic factors such as brain-derived growth factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VGEF), and transform growth factor-β (TGF-β). Flavonoids prevent neurodegeneration and brain aging via reduction of induced nitric oxide synthase (iNOS), nitric oxide releasing, suppression inflammatory cytokines, such as TNF-α, IL-1β.\[[@ref50][@ref51]\] Quercetin as a flavonoid which is present in *R. damascena* attenuates microglia- and/or astrocyte-mediated neuroinflammation.\[[@ref52]\] Many neurodegenerative diseases pathogenesis including Alzheimer\'s disease correlate to oxidative stress enhancement in brain.\[[@ref16]\] Brain biological functions of flavonoids attribute to their antioxidant functions.\[[@ref53]\] Phenolic compounds are effective hydrogen donors, and because of this they are known as good antioxidants.\[[@ref54]\] Their high antioxidant potential is attributed to their capacity of scavenging reactive oxygen species (ROS), inhibiting lipid peroxidation, chelating metal ions, and other free radicals, which are originated from various cellular activities and lead to oxidative stress.\[[@ref55]\] The cholinergic system is involved in many physiological processes, including synaptic plasticity and learning and memory.\[[@ref56][@ref57]\] Quercetin and rutin, natural compounds widely found in *R. damascena* and diet have anticholinesterase inhibition effects without severe side effects.\[[@ref58]\] Recent studies have focused on amyloid precursor protein (APP) proteolysis and Aβ-generation as potential targets for AD therapy.\[[@ref59]\] Aβ is generated from the APP by beta-site APP cleaving enzyme-1 (BACE-1, β- secretase) and γ-secretases through pro-amyloidogenic processing pathway, but α-secretase via nonamyloidogenic processing pathway inhibits Aβ production and promote Aβ degradation.\[[@ref60]\] Myricetin, one of the natural flavonoids has been found in *R. damascena* is a strong antioxidant and has a dual neuroprotective effect by activation of α-secretase and direct inhibition of β-secretase (BACE-1). As myricetin-bound BACE-1 does not hydrate APP at the β-cleavage site, Aβ production would be reduced. It has three hydrogen-binding groups, which stabilize BACE-1 binding for concerning AD drug therapy.\[[@ref60][@ref61]\] Myricetin binds also to Aβ through its hydroxyl arms and traps Aβ hydrogen bond, which is necessary to form β-structures or oligomers.\[[@ref62]\] Myricetin via this mechanism prevents Aβ structural alteration from a random coil to β-sheet and inhibits Aβ fibril generation. The β-structure of Aβ forms soluble oligomers that are considered to be AD cytotoxic component.\[[@ref7][@ref63]\] It is demonstrated that quercetin also disrupts the β-sheet structure to form random coils.\[[@ref61][@ref64]\] Therefore *R. damascena* with high concentration of quercetin, myricetin, and other flavonoids decreases level of Aβ (1--42) in brain and finally improves learning and memory.

CONCLUSION {#sec1-5}
==========

In summary, *R. damascena* reversed the Aβ-associated memory abnormalities in a rat model of amyloid-β-induced Alzheimer\'s disease. Taken together, the diverse actions of individual natural components of the *R. damascena* on learning and memory represent a new promising way for generation of memory-enhancing drugs, although complementary experiments are still to be down for better characterizing this valuable effect and its underlying mechanisms, in order to provide a basis for proper clinical trials.
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